[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053935":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Mahidol University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"study arm","EXPERIMENTAL","olanzapine palonosetron with dexamethasone on day 1 only",[13],"Drug: dexamethasone sparing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","dexamethasone sparing","omit dexamethasone on day 2-4",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Suthinee Ithimakin","CONTACT","+66898127440","aesi105@yahoo.co.th",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Faculty of Medicine Siriraj Hospital, Mahidol University","RECRUITING","Bangkok","10700","Thailand","TH",{"type":36,"coordinates":37},"Point",[38,39],100.50144,13.75398,{"lat":39,"lon":38},[42,44,47,50],{"name":23,"role":24,"phone":43,"phoneExt":20,"email":26},"0898127440",{"name":45,"role":46,"phone":20,"phoneExt":20,"email":20},"Sirisopa Techawattanawanna, M.D","PRINCIPAL_INVESTIGATOR",{"name":48,"role":49,"phone":20,"phoneExt":20,"email":20},"Akarin Nimmannit, M.D","SUB_INVESTIGATOR",{"name":51,"role":49,"phone":20,"phoneExt":20,"email":20},"Visullaya Sa-nguanwongwan, M.D",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100053935","phase-2-steroid-sparing-regimen-with-olanzapine-and-palonosetron-for-emetic-prevention-for-high-dose-cisplatin-100053935",false,"NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin","ALL","18 Years",{"count":64,"type":65},95,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[71,72,73,74],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[76,77,17,78],"cisplatin","chemotherapy induced nausea vomiting","olanzapine","2026-07-07",{"date":81,"type":82},"2026-07-13","ACTUAL",{"date":84,"type":82},"2026-02-10",{"date":86,"type":65},"2027-11-15",{"name":5,"class":6},1]